Call for abstracts
Dear colleagues in reproductive medicine!
The call for abstracts to NFS 2024 is now open. At NFS 2024 we want to offer the opportunity for researchers to
present their work to international colleagues in a Nordic setting. Submitting an abstract to NFS 2024 is potentially a
great way for early-career researchers, and others, to disseminate their research-findings.
Also, the best abstract will receive a prize.
The submitted abstracts will be reviewed by the local organizing committee who will call on external
scientific consultants for additional review if required. The outcome of the review process is either
a) accepted for oral presentation AND poster
b) accepted for poster only
c) rejected.
The formal requirements for abstracts to NFS 2024 are similar to those of the journal “Human Reproduction” and include:
Scope of NFS 2024 abstracts:
We welcome abstracts from research on the clinical science and medical aspects of reproductive physiology, pathology,
epidemiology and endocrinology; including andrology, gonad function, gametogenesis, fertilization, embryo development,
implantation, early pregnancy, reproductive genetics, genetic diagnosis, oncology, infectious disease, surgery, contraception,
infertility treatment, psychology, ethics and social issues, quality-control, management of IVF-units.
Please note that we will reject abstracts concerning planned studies without current results.
Deadline for submitting NFS 2024 abstracts:
14th April 2024 at 23:59 CET
Address for submitting NFS 2024 abstracts:
Abstracts should be sent by the corresponding author by email as a single-file attachment in MS Word format to nfs2024@sthf.no.
The subject of the email should be: NFS2024 abstract.
Language of NFS 2024 abstracts:
English
Format of NFS 2024 abstracts:
Word count: [Maximum 400]
Title: [Should not exceed 25 words and should be specific and informative. Trade marks and proprietary terms are not allowed in the title].
Authors: [Give initials and family name of all authors with author affiliations and addresses: The department, institution, city and country should be given for each author. An e-mail address must be stated for the corresponding author, who should be clearly identified with an asterisk. A back-up corresponding author should also be clearly identified and their e-mail address stated.]
Study question: [A SINGLE question (ending in a question mark), limited to the PRIMARY objective of the study ONLY
(do not include secondary questions)]
Summary answer: [The main conclusion. A single sentence, this should be limited to the primary results
of the study, without any discussion of their implications]
What is known already: [One or two short sentences]
Study design, size, duration: [cohort study, case control study, cross sectional study, diagnostic test; sample size calculation;
total number of subjects involved; time period in which study was performed]
Participants/materials, setting, methods: [matching criteria (for matched studies), numbers exposed/unexposed,
numbers of controls per case, distribution of severity of disease in those with target condition]
Main results and the role of chance:
Limitations, reasons for caution: [bias, confounding, power]
Wider implications of the findings: [generalizability to other populations, agreement/disagreement
with literature, resolution of previous disparity, new insights]
Study funding/competing interest(s): [all funding sources for the study and potential conflicts of interest for all authors should be listed]
Trial registration number: [please include trial registration number if registered in an ICMJE-recognized trial registry (see http://www.icmje.org/faq.pdf)]
Deadline for decision by committee on NFS 2024 abstracts:
24th April 2024 at 23:59 CET, before which corresponding author will be contacted by e-mail.
The call for abstracts to NFS 2024 is now open. At NFS 2024 we want to offer the opportunity for researchers to
present their work to international colleagues in a Nordic setting. Submitting an abstract to NFS 2024 is potentially a
great way for early-career researchers, and others, to disseminate their research-findings.
Also, the best abstract will receive a prize.
The submitted abstracts will be reviewed by the local organizing committee who will call on external
scientific consultants for additional review if required. The outcome of the review process is either
a) accepted for oral presentation AND poster
b) accepted for poster only
c) rejected.
The formal requirements for abstracts to NFS 2024 are similar to those of the journal “Human Reproduction” and include:
Scope of NFS 2024 abstracts:
We welcome abstracts from research on the clinical science and medical aspects of reproductive physiology, pathology,
epidemiology and endocrinology; including andrology, gonad function, gametogenesis, fertilization, embryo development,
implantation, early pregnancy, reproductive genetics, genetic diagnosis, oncology, infectious disease, surgery, contraception,
infertility treatment, psychology, ethics and social issues, quality-control, management of IVF-units.
Please note that we will reject abstracts concerning planned studies without current results.
Deadline for submitting NFS 2024 abstracts:
14th April 2024 at 23:59 CET
Address for submitting NFS 2024 abstracts:
Abstracts should be sent by the corresponding author by email as a single-file attachment in MS Word format to nfs2024@sthf.no.
The subject of the email should be: NFS2024 abstract.
Language of NFS 2024 abstracts:
English
Format of NFS 2024 abstracts:
Word count: [Maximum 400]
Title: [Should not exceed 25 words and should be specific and informative. Trade marks and proprietary terms are not allowed in the title].
Authors: [Give initials and family name of all authors with author affiliations and addresses: The department, institution, city and country should be given for each author. An e-mail address must be stated for the corresponding author, who should be clearly identified with an asterisk. A back-up corresponding author should also be clearly identified and their e-mail address stated.]
Study question: [A SINGLE question (ending in a question mark), limited to the PRIMARY objective of the study ONLY
(do not include secondary questions)]
Summary answer: [The main conclusion. A single sentence, this should be limited to the primary results
of the study, without any discussion of their implications]
What is known already: [One or two short sentences]
Study design, size, duration: [cohort study, case control study, cross sectional study, diagnostic test; sample size calculation;
total number of subjects involved; time period in which study was performed]
Participants/materials, setting, methods: [matching criteria (for matched studies), numbers exposed/unexposed,
numbers of controls per case, distribution of severity of disease in those with target condition]
Main results and the role of chance:
Limitations, reasons for caution: [bias, confounding, power]
Wider implications of the findings: [generalizability to other populations, agreement/disagreement
with literature, resolution of previous disparity, new insights]
Study funding/competing interest(s): [all funding sources for the study and potential conflicts of interest for all authors should be listed]
Trial registration number: [please include trial registration number if registered in an ICMJE-recognized trial registry (see http://www.icmje.org/faq.pdf)]
Deadline for decision by committee on NFS 2024 abstracts:
24th April 2024 at 23:59 CET, before which corresponding author will be contacted by e-mail.
